Floatz logo

TRIPRO-AMYLIN

Alzheimer Disease

Boston Universityprotein_peptideEarly Phase 1Active
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
65/ 100

Competitive context

203 Active assets in the Alzheimer Disease cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Eli Radiopharma
Phase 4BBB
Florbetaben
National Institute of Mental Health (NIMH)
Phase 4BBB
Galantamine Hydrobromide
Janssen Cilag Pharmaceutica S.A.C.I., Greece
Phase 4BBB
Donanemab
Michael Rafii, MD, PhD
Phase 4BB
AMILOMOTIDE
Novartis Pharmaceuticals
Phase 2/3BB

View all 50 →

Same molecule, other indications

TRIPRO-AMYLIN is also rated in:

obesity disorderDormant
BB
Indicative ·
65 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative ·
65 / 100
View asset →
diabetes mellitusDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →